Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345844 | 0.90 | PRCP (0.64) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL2585704 | 0.89 | PRCP (0.51) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL2586436 | 0.87 | PRCP (0.51) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL2586341 | 0.87 | PRCP (0.57) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL1745724 | 0.82 | PRCP (0.57) | PRCPOPRM1OPRD1CYP1A2CYP3A4 | |
| SCHEMBL12565050 | 0.81 | PRCP (0.63) | PRCPHCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL1747164 | 0.80 | PRCP (0.55) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL3343810 | 0.78 | PRCP (0.54) | PRCPOPRM1OPRD1CYP1A2CYP3A4 | |
| SCHEMBL1747409 | 0.78 | PRCP (0.69) | PRCPHCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL1746075 | 0.78 | CYP3A4 (0.56) | PRCPOPRM1OPRD1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885OPRM1 2169/4885OPRD1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.